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The reduced protein expression of SIRT6 tumor sup-
pressor is involved in tumorigenesis. The molecular
mechanisms underlying SIRT6 protein downregula-
tion in human cancers remain unknown. Using a
proteomic approach, we have identified the ubiqui-
tin-specific peptidase USP10, another tumor sup-
pressor, as one of the SIRT6-interacting proteins.
USP10 suppresses SIRT6 ubiquitination to protect
SIRT6 from proteasomal degradation. USP10 antag-
onizes the transcriptional activity of the c-Myc
oncogene through SIRT6, as well as p53, to inhibit
cell-cycle progression, cancer cell growth, and
tumor formation. To support this conclusion, we de-
tected significant reductions in both USP10 and
SIRT6 protein expression in human colon cancers.
Our study discovered crosstalk between two
tumor-suppressive genes in regulating cell-cycle
progression and proliferation and showed that dys-
regulated USP10 function promotes tumorigenesis
through SIRT6 degradation.
INTRODUCTION
Reduced expression and loss-of-function mutation of tumor
suppressor genes are common molecular mechanisms that
contribute to tumor development, progression, and metastasis.
The sirtuin family histone deacetylase member SIRT6 was
recently shown to be a tumor suppressor, and reduced SIRT6
expression has been detected in human primary cancers
(Sebastia´n et al., 2012). SIRT6 functions as a tumor suppressor
through multiple molecular mechanisms. Early studies showed
that SIRT6 is a chromatin-bound factor that maintains genomic
stability (Mostoslavsky et al., 2006). It localizes to telomeres in
human cells and controls cellular senescence and telomere
structure by deacetylating histone H3 lysine 9 (H3K9) (Michishita
et al., 2008). SIRT6 also promotes DNA end resection by deace-Cell Retylating CtBP-interacting protein (Kaidi et al., 2010). SIRT6 is also
important in suppressing gene transcription of transcription fac-
tors, such as HIF-1a and c-myc, or it is recruited to chromatin by
transcription factors, such as NF-kB and AP-1, thus deacetylat-
ing histone H3K9 to regulate gene transcription (Kawahara et al.,
2009; Sebastia´n et al., 2012; Tasselli and Chua, 2012; Zhong
et al., 2010). Therefore, SIRT6 exerts its functions through multi-
ple molecular mechanisms.
It has been reported that the expression of SIRT6 can be
regulated at both the transcriptional and posttranscriptional
levels. The transcription factors FOXO3a and NRF1 directly
bind to the SIRT6 promoter and positively regulate expression
of SIRT6, which, in turn, negatively regulates glycolysis (Kim
et al., 2010). At the posttranscriptional level, the AP-1 family tran-
scription factor c-Fos induces SIRT6 transcription to suppress
the antiapoptotic activity of survivin by reducing histone H3K9
acetylation and NF-kB activation (Min et al., 2012). A recent
study has suggested that microRNA-34a/b targets SIRT6 to
regulate fatty acid metabolism and insulin signaling, indicating
that posttranscriptional regulation is involved in SIRT6 expres-
sion (Da´valos et al., 2011). However, the factors that regulate
SIRT6’s biological functions at the posttranslational levels have
not been identified.
USP10 is a member of the mammalian ubiquitin-specific pep-
tidases (USPs). Although its biological functions remain largely
unknown, evidence suggests that USP10 might suppress
tumors by reversing Mdm2-induced p53 nuclear export and
degradation (Jochemsen and Shiloh, 2010; Yuan et al., 2010).
Hence, USP10 suppresses tumor cell growth in cells with wild-
type p53. More recently, it was shown that Beclin1, a tumor
suppressor that is frequently lost in human cancers, controls
the protein stability of USP10 as well as USP13, thus regulating
their deubiquitinating activities. Given that USP10 mediates the
deubiquitination of p53, regulation of the deubiquitination activity
of USP10 by Beclin1 likely plays an important role in tumor sup-
pression (Jochemsen and Shiloh, 2010; Liu et al., 2011; Yuan
et al., 2010).
By using a proteomic approach, we identified USP10 as an
interaction partner of SIRT6. This finding implies that they form
a regulatory mechanism. In fact, further studies indicated thatports 5, 1639–1649, December 26, 2013 ª2013 The Authors 1639
Figure 1. Identification of SIRT6 Interactome
(A) FLAG-SIRT6 pull-down products from HCT116 cells were separated by SDS-PAGE and visualized by silver staining.
(B) SIRT6-interacting proteins were identified by mass spectrometry. The total peptide numbers of each protein are indicated.
(C) Classification of SIRT6-associated proteins. The pathways matched to the candidates in (B) with the same colors.USP10 is a SIRT6-specific deubiquitinase that suppresses
tumor growth by antagonizing transcriptional activity of the
oncogene c-myc. Suppression of USP10 expression promotes
human colon cancer cell growth and tumor formation through
proteasomal degradation of SIRT6. Of note, we further dis-
covered that human colon cancer tissues had reduced
protein expression of both USP10 and SIRT6 compared with
adjacent normal tissues. These studies reveal a molecular
mechanism underlying impaired SIRT6 protein expression in
tumorigenesis.
RESULTS
Identification of a Highly Specific SIRT6 Interactome
To determine the molecular mechanisms underlying the
impaired protein expression of the tumor suppressor SIRT6 in
tumorigenesis, we used a proteomic approach and identified
SIRT6 interaction proteins from HCT116 cells, as we recently re-
ported (Lin et al., 2012). Briefly, whole-cell lysate from FLAG-
SIRT6 expressing cells was subjected to immunoprecipitation
with anti-FLAG-conjugated agarose beads after extensive pre-
cleaning. The beads were washed and eluted with 3 3 FLAG
peptide. A small fraction of the eluent was subjected to SDS-
PAGE and silver staining; multiple bands, including a strong
SIRT6 protein band, were visualized (Figure 1A). The rest of elu-
ents were analyzed by mass spectrometry after trypsin diges-
tion. As indicated in Figure 1B, 26 proteins have been identified
by this approach, many of which are involved in a variety of bio-
logical functions, including signal transduction, RNA processing,
ubiquitination, and proteolysis, metabolism, and nuclear acid
binding (Figure 1C), indicating that SIRT6 is likely involved in
different aspects of biological functions. We then validated
SIRT6 interactors by coimmunoprecipitation (co-IP) and western
blotting. Of the 26 candidate interactors, 16 were confirmed to
be SIRT6-specific interacting proteins (Figure S1), and four are
the known SIRT6-interacters, including PARP1 (Mao et al.,
2011), histones H3, H4b, and H1FX (Kawahara et al., 2009; Mich-
ishita et al., 2008; Zhong et al., 2010). More interestingly, G3BP2,
a previously known USP10-interacting protein (Matsuki et al.,
2013; Ward et al., 2011), was detected in the SIRT6-pull-down1640 Cell Reports 5, 1639–1649, December 26, 2013 ª2013 The Autproducts, suggesting that SIRT6 forms a complex with USP10
and G3BP2. Whereas some candidates, such as MAP3K7,
were confirmed as true SIRT6 interactors with only a single pep-
tide detected by mass spectrometry, no more than two peptides
were detected for all five false-positive candidates (Figures 1B,
S1, and S2). Those results showing a positive correlation of the
peptide numbers indicate that our proteomic approach revealed,
with confidence, true SIRT6 interactors.
USP10 Interacts with SIRT6
The ubiquitin-specific peptidase USP10, a tumor suppressor
that often has low expression in human cancers (Yuan et al.,
2010), was confirmed as aSIRT6 interaction partner (Figure S1A).
Because USP10 is a deubiquitinase that can protect its interac-
tion partners from ubiquitin-mediated degradation (Draker et al.,
2011; Yuan et al., 2010), we speculated that the reduction of
SIRT6 protein might be a functional consequence of USP10
reduction in human cancers. To test this hypothesis, we vali-
dated the specificities of USP10 and SIRT6 interactions. As indi-
cated in Figure 2A, USP10 interacts with SIRT6 but not with any
of the other six sirtuin family proteins. Conversely, SIRT6
specifically interacts with USP10 but not with USP22 or USP47
(Figure 2B). Moreover, the specific interaction between the
endogenous USP10 and SIRT6 was confirmed in HCT116 colon
cancer cells because SIRT6 protein was detected in the immu-
noprecipitates with anti-USP10, but not with the control mouse
immunoglobulin (Ig) G (Figure 2C). Therefore, we identified
USP10 as a specific interacting protein of SIRT6.
Next, we mapped the regions of USP10 that mediate its inter-
action with SIRT6 by generating truncated mutants (Figure 2D).
USP10 protein carries a C-terminal C19 peptidase domain and
an N-terminal regulatory region. Co-IP and western blotting
analysis revealed that the N-terminal regulatory domain of
USP10 is required for its interaction with SIRT6, as deletion of
this region completely abolished its interaction with SIRT6. In
contrast, expression of the USP10 N-terminal 1-205 fragment
alone is sufficient to pull SIRT6 protein down (Figure 2E). Simi-
larly, truncated mutation analyses showed that the C terminus
of SIRT6 is required for its interaction with USP10 (Figures 2F
and 2G).hors
Figure 2. USP10 Specifically Interacts with and Deubiquitinates SIRT6
(A) USP10 specifically interacts with SIRT6. The expression plasmid of Myc-USP10 was transiently transfected with each of the indicated FLAG-SIRTuins into
HCT116 cells. Their interactions were examined by co-IP with anti-FLAG Abs and by western blotting with anti-Myc Abs (top), and the same membranes were
reprobed with anti-Myc (second panel). The protein expression levels of SIRT1-7 in whole-cell lysates were confirmed by western blotting (bottom).
(B) SIRT6 interaction with each of the indicated USPs was analyzed as in (A).
(C) The interaction of endogenous USP10 and SIRT6 in human colon cancer cells. Cell lysates were precleaned and then subjected to immunoprecipitation with
anti-USP10 specific Abs using normal mouse IgG as a control. The bound SIRT6 was determined by western blotting with anti-SIRT6 Abs (top). The protein
expression levels of USP10 (middle) and SIRT6 (bottom) in the whole-cell lysate were confirmed by western blotting.
(D) Domain structures of USP10 and its truncated mutants. USP10 protein has a conserved catalytic domain in its C terminus.
(E) HA-SIRT6 plasmid was cotransfected with USP10 or with each of its truncated mutants. Their interactions were determined as described in (A).
(F) Domain structures of SIRT6 and its truncated mutants. SIRT6 protein has a conserved HDAC domain or SIRTuin/SIRT domain, indicated in red.
(G) Myc-USP10 plasmid was cotransfected with FLAG-tagged SIRT6 or each of its truncated mutants. Their interaction was determined as described in (A).
(H) FLAG-SIRT6 and HA-ubiquitin expression plasmid DNA was cotransfected with USP10, USP/CAmutant, or USP22 into HCT116 cells. SIRT6 ubiquitination in
transiently transfected cells was analyzed by co-IP with anti-FLAG Abs and western blotting with anti-HA Abs (top). The protein expression levels of SIRT6 were
confirmed by western blotting (middle).
(I) Ubiquitinated FLAG-SIRT6 proteins in transiently transfected HCT116 cells were pulled down by anti-FLAG-conjugated beads, followed by incubation with
purified GST-USP10, GST-USP10/CA, or GST-USP22 proteins. SIRT6 ubiquitination levels were determined by western blotting with anti-HA (top), and SIRT6
and GST or GST fusion proteins were confirmed by western blotting (bottom two panels).
(J) HCT116 colon cancer cells were transfected with shRNA specifically against USP10 or USP22 using a commercial control shRNA (ctrl). The effects of USP10
or USP22 knockdown on SIRT6 ubiquitination were determined as described in (G). Tubulin was used as loading control.USP10 Negatively Regulates SIRT6 Ubiquitination
Because USP10 suppresses the ubiquitination of its interacting
proteins, which protects them from degradation (Draker et al.,
2011; Yuan et al., 2010), we analyzed the effect of USP10Cell Reexpression on SIRT6 ubiquitination. We detected SIRT6 protein
ubiquitination in transiently transfected HCT116 cells (Figure 2H,
lane 1). Coexpression of wild-type USP10 with SIRT6 signifi-
cantly inhibited its ubiquitination (Figure 2H, lane 2). In contrast,ports 5, 1639–1649, December 26, 2013 ª2013 The Authors 1641
Figure 3. USP10 Protects SIRT6 Protein from Degradation
(A and B) USP10 expression plasmids or empty vectors were transfected into HCT116 cells. The transfected cells were treated with cycloheximide (CHX) for
different times. The protein levels in the treated cells were determined by western blotting using anti-SIRT6 (top) and anti-FLAG Abs (middle). Tubulin was used as
a loading control (bottom) (A). The band intensities of SIRT6 proteins were quantified, and their relative levels are shown in (B).
(C) A fraction of cells from (A) was prepared in parallel for total RNA extraction. The mRNA levels of both USP10 and SIRT6 were determined by real-time PCR.
Their relative levels are indicated. The error bar represents the SEM of triplicate experiments. *p < 0.05, two-tailed Student’s t test.
(D and E) USP10 or USP10/CA mutant plasmids were transfected into HCT116 cells. SIRT6 protein stabilities in the transiently transfected HCT116 cells were
examined as described in (A) and (B).
(F and G) HCT116 cells were transfected with control shRNA or with shRNA specifically against USP10 or USP22. SIRT6 protein stabilities were analyzed as
described in (A) (top). The expression levels of USP10 (second) and USP22 (third) were confirmed by western blotting using tubulin as a loading control (bottom)
(F). The relative expression levels of SIRT6 protein are indicated (G).
(H) The relative mRNA levels of SIRT6, USP10, and USP22 in cells used in (F) and (G) were analyzed by real-time PCR. The error bars represent the SEM of
triplicate experiments. *p < 0.05, two-tailed Student’s t test.
(I) USP10 or USP10/CA mutant plasmids were transfected into HCT116 cells and treated with the proteasome inhibitor MG132 as indicated 48 hr after trans-
fection. The protein levels of SIRT6 (top) and USP10 (middle) were determined by western blotting using tubulin as loading control (bottom).the deubiquitinase catalytically inactive USP10/CA mutant failed
to suppress SIRT6 ubiquitination (Figure 2H, lane 3). USP10-
mediated SIRT6 deubiquitination is highly specific, because
coexpression of USP22, which was recently shown to be a
SIRT1-specific deubiquitinase (Lin et al., 2012), did not have
any effect on SIRT6 ubiquitination (Figure 2H, lane 4). The sup-
pression of SIRT6 ubiquitination by the deubiquitinase activity
of USP10was further confirmed by using an in vitro deubiquitina-
tion assay. Incubation of ubiquitinated SIRT6 with a purified
GST-USP10 fusion protein, but not with the GST-USP10/CA
mutant or the GST-USP22 fusion protein, inhibited SIRT6 ubiqui-
tination (Figure 2I). Conversely, suppression of USP10 by small-
hairpin-RNA (shRNA)-mediated knockdown in HCT116 cells
resulted in elevated SIRT6 ubiquitination. As a control, SIRT6
ubiquitination was not affected by shRNA specific to USP22
(Figure 2J). Together with the fact that USP10 interacts with1642 Cell Reports 5, 1639–1649, December 26, 2013 ª2013 The AutSIRT6, our studies indicate that USP10 is a specific deubiquiti-
nase of SIRT6.
USP10 Protects SIRT6 Protein from Proteasome-
Mediated Degradation
Ubiquitination promotes protein degradation, which can be
reversed by ubiquitin-specific peptidases. Our discovery that
USP10 is a deubiquitinase of SIRT6 implies that USP10 might
regulate SIRT6 protein stability. Indeed, gain of USP10 functions
by transient transfection resulted in elevated SIRT6 protein ex-
pression and prolonged half-life of SIRT6 proteins in HCT116
cells (Figures 3A and 3B). In contrast, mRNA expression levels
of SIRT6 were not affected by USP10 expression (Figure 3C).
Expression of a deubiquitinase catalytically inactive USP10/CA
mutant failed to protect SIRT6 from degradation, indicating
that SIRT6 stabilization requires ubiquitin-specific peptidasehors
Figure 4. USP10 Inhibits c-Myc Transcriptional Activity
(A) Total RNA fromHCT116 cells expressing indicated plasmids or combination were extracted (sh-USP10 and sh-SIRT6: sh-RNA-mediated knockdown; USP10
and SIRT6: overexpression). The level of each indicated c-Myc target gene was analyzed by real-time PCR using b-actin as an internal control. The error bars
represent the SEM of triplicate experiments.
(B) USP10 expression plasmids or empty vectors were transfected into HCT116 cells. The transfected cells were crosslinked 48 hr later with 1% formaldehyde for
10min and lysed with SDS lysis buffer. ChIP assay was performed according to the manufacturer’s protocol by ChIP with anti-SIRT6. QPCRwas then performed
with c-Myc target gene primers. The experiment was performed in triplicate, and data were represented as the means ± SD. The asterisks indicate a statistically
significant difference (*p < 0.05).
(C) c-Myc target gene promoter sequences were amplified from genomic DNA pulled down by ac-H3K9 CHIP and analyzed as in (A). The asterisks indicate a
statistically significant difference (*p < 0.05; **p < 0.01).
(D) HCT116 cells were transfected with USP10 or with SIRT6 expression plasmids or both, or with their specific shRNAs as indicated. Three days after trans-
fection, cell-cycle progression was determined by propidium iodide staining followed by flow cytometry. The percentage of cells in each indicated cell-cycle
stage is shown.activity by USP10 (Figures 3D and 3E). Conversely, shRNA-
mediated knockdown of USP10 decreased the endogenous
SIRT6 protein levels without affecting SIRT6 mRNA levels (Fig-
ures 3F–3H). As a negative control, suppression of USP22
expression did not affect SIRT6 protein stability (Figure 3F).
Moreover, we found that treatment of cells with the protea-
some-specific inhibitor MG132 protected SIRT6 from degrada-
tion (Figure 3I), suggesting that SIRT6 protein degradation
occurs through the proteasomal pathway. Taken together, our
results indicate that USP10 is a SIRT6-specific deubiquitinase
that protects SIRT6 protein from ubiquitin-mediated degradation
through the proteasomal pathway. The same conclusion was
further confirmed using another colon cancer cell line RKO that
expresses a wild-type p53 gene. As shown in Figure S3, overex-
pression of USP10 but not its CA mutant prolonged SIRT6 half-
life. In contrast, knockdown of USP10 but not USP22 in RKO
cells promoted SIRT6 degradation.
USP10 Inhibits c-Myc Transcriptional Activity
Recent studies have shown that one of the molecular mecha-
nisms by which SIRT6 carries out its tumor-suppressive function
is through suppressing the transcriptional activity of the c-MycCell Reoncogene (Sebastia´n et al., 2012). Thus, we determined whether
USP10 functions as a tumor suppressor through SIRT6-medi-
ated c-Myc inactivation. In fact, we demonstrated that USP10
knockdown in human colon cancer cells leads to elevated
expression of c-Myc target genes, including the proliferating
cell nuclear antigen (PCNA) (Gazitt et al., 1993), cell division con-
trol protein 2 (cdc2), cyclin A1 (CCNA1), and cdc25c (Charollais
et al., 1990; Dalal et al., 1999; Furukawa et al., 1990), presumably
because USP10 knockdown resulted in increased c-Myc tran-
scriptional activity. We then reasoned that, if USP10 suppresses
c-Myc transcriptional activity through SIRT6 stabilization,
knockdown of SIRT6 expression should achieve a similar level
of increase in c-Myc target gene expression in human colon can-
cer cells. To our surprise, SIRT6 gene suppression resulted in a
lower level of increase in c-Myc target gene expression than that
of USP10 knockdown, implying that additional factors may
contribute to USP10-mediated c-Myc suppression. To support
this notion, overexpression of SIRT6 only partially suppressed
the elevated c-Myc target gene expression caused by USP10
gene knockdown (Figure 4A). It has been shown that SIRT6
can be recruited to the chromatin by specific transcription fac-
tors to suppress gene transcription through antagonizing histoneports 5, 1639–1649, December 26, 2013 ª2013 The Authors 1643
Figure 5. Inhibition of c-Myc Activity by USP10 Depends on Both SIRT6 and p53
(A) Wild-type or p53/ HCT116 cells stably expressing the control shRNA or specific to USP10 (sh-USP10) or SIRT6 (sh-SIRT6) or with USP10 expression
plasmid at each indicated combination. Total RNA was extracted from and the levels of c-Myc target genes were analyzed by real-time PCR using b-actin as an
internal control. The error bars represent the SEM of triplicate experiments.
(B) Total RNAwas extracted fromwild-type or SIRT6/MEF cells expressing indicated plasmids or combination of plasmids and the levels of c-Myc target genes
were analyzed as in (A).
(C) HCT116 cells were transfected with indicated combinations of plasmids. Three days after transfection, the cell-cycle stage was determined by PI staining and
flow cytometry. The percentage of cells in each cell-cycle stage is indicated.acetylation at the specific promoter regions (Kawahara et al.,
2009; Zhong et al., 2010). Indeed, we detected the elevated pro-
moter binding of SIRT6 in cells with USP10 overexpression (Fig-
ure 4B). As a consequence, the levels of the lysine 9 acetylation
in histone H3 protein (H3K9) at the promoters of c-Myc targets
were significantly reduced (Figure 4C). Collectively, our results
indicate that USP10 suppresses c-Myc transcriptional activity
partially through SIRT6.
The oncogene c-Myc is a transcription factor that promotes
tumor cell-cycle progression by regulating the expression levels
of genes that are involved in cell-cycle progression (Charollais
et al., 1990; Charollais and Mester, 1988; Dalal et al., 1999;
Ely et al., 1987; Furukawa et al., 1990; Gazitt et al., 1993; Kelly
et al., 1983). We then determined whether USP10 and SIRT6
act as tumor suppressors by inhibiting the cell-cycle progression
of cancer cells. As expected, ectopic expression of either USP10
or SIRT6 led to a significant reduction in the percentage of cells in
the G2/M and S phases, and coexpression of both USP10 and
SIRT6 achieved synergistic suppression of colon cancer cell-
cycle progression (Figure 4D). Conversely, knockdown of either
USP10 or SIRT6 facilitated cell-cycle progression by increasing
the percentage of cells at S and G2/M phases. By knockdown of1644 Cell Reports 5, 1639–1649, December 26, 2013 ª2013 The Autboth USP10 and SIRT6, we also confirmed their synergy in pro-
moting cell-cycle progression (Figure 4D). Because one of the
molecular mechanisms by which SIRT6 achieves its tumor-sup-
pressive functions is through c-Myc inhibition (Sebastia´n et al.,
2012), our results suggest that USP10 inhibits the c-Myc onco-
gene, at least partially, through SIRT6 stabilization.
USP10 Suppresses c-Myc Transcriptional Activity
through SIRT6 and p53
Our results in Figure 4 imply that additional factors are involved in
USP10-mediated c-Myc suppression. It has been reported that
one of the molecular mechanisms underlying USP10 tumor-sup-
pressive functions is that it protects p53 from degradation (Yuan
et al., 2010), raising the possibility that USP10 also antagonizes
c-Myc transcriptional activity through p53. To test this, we
compared the c-Myc-suppressing activities of USP10 in p53
wild-type and p53/ HCT116 human colon cancer cells. As
shown in Figure 5A, the expression levels of c-Myc target gene
were elevated in p53/ HCT116 cells compared to HCT116
cells carrying a wild-type p53 gene, confirming previous studies
showing that p53 antagonizes c-Myc transcriptional activity
(Aguda et al., 2011; Golomb et al., 2012; Ho et al., 2005; Kresshors
et al., 2011; Rochlitz et al., 1995; Wang et al., 2010). Expression
of USP10 significantly suppressed c-Myc transcriptional activity
in p53 wild-type and p53/ HCT116 cells, but the levels of
USP10-mediated suppression in c-Myc target gene transcrip-
tion in p53-null cells were partially reversed. These results indi-
cate that p53 is downstream of USP10 in suppressing c-Myc
transcriptional activity, but additional factors, one of which pre-
sumably is SIRT6 as indicated from our results in Figure 4A,
are involved in USP10-mediated c-Myc suppression. To support
this speculation, we discovered that knockdown of USP10
expression resulted in dramatic elevations in the transcription
of c-Myc target genes (Figure 5A). Notably, USP10 knockdown
largely diminished the differences in c-Myc target gene expres-
sion levels between wild-type and p53/ HCT116 cells, indi-
cating that loss of USP10 releases the suppressive activity of
both SIRT6 and p53 to c-Myc target gene transcription. To
further prove the principle that USP10 suppresses c-Myc tran-
scriptional activity through both SIRT6 and p53, we tested
whether knockdown of SIRT6 rescues this USP10-suppressive
activity. Indeed, knockdown of SIRT6 in p53+/+ cells partially
reversed the suppressive activity of USP10. In contrast, the sup-
pressive activity of USP10 to c-Myc transcriptional activity was
completely reversed by SIRT6 knockdown in p53-null cells (Fig-
ure 5A), providing a direct evidence that SIRT6 is involved in
c-Myc suppression in the absence of p53.
We then used SIRT6-null mouse embryonic fibroblasts (MEFs)
to prove the principle that SIRT6 is another downstream factor in
USP10-mediated c-Myc suppression. Similar to that in p53/
cells, a significant increase in c-Myc transcriptional activity in
SIRT6-deficient MEFs was detected (Figure 5B), confirming
SIRT6 as a c-Myc suppressor (Sebastia´n et al., 2012). Consistent
with the results shown in Figure 5A, USP10 knockdown resulted
in a dramatic increase in c-Myc target gene transcription both in
wild-type and in SIRT6/ MEF cells, and differences in c-Myc
target gene expression levels between the wild-type and in
SIRT6/MEF cells are largely reduced. Conversely, expression
of USP10 significantly suppressed c-Myc target gene transcrip-
tion both in wild-type MEFs, and the USP10-suppressive activity
of c-Myc target gene expression was partially reversed in
SIRT6/MEFs (Figure 5B), further suggesting that other factors,
such as p53, are involved in USP10-mediated c-Myc suppres-
sion. To support this, p53 knockdown in SIRT6/MEFs resulted
in a significant increase in c-Myc target gene transcription, which
is to a similar level as that ofUSP10 knockdown. In addition, p53
knockdown partially abolished USP10 overexpression-medi-
ated suppression in c-Myc target gene expression in SIRT6+/+
MEFs, and p53 knockdown in SIRT6/ MEFs fully reversed
USP10-mediated suppression of c-Myc targets expression (Fig-
ure 5B). Based on the results from experiments using both p53-
null HCT116 cells and SIRT6-null MEFs, we conclude that
USP10 regulates c-Myc transcriptional activity through both
p53 and SIRT6.
Furthermore, USP10 knockdown-mediated cell-cycle pro-
gression was partially rescued by either SIRT6 or p53 coex-
pression. A complete rescue was achieved by p53 and SIRT6
coexpression in the USP10 knocked down cells (Figure 5C).
Collectively, these studies indicate that one of the molecular
mechanisms by which USP10 achieves tumor suppression isCell Rethrough potentiating both SIRT6- and p53-mediated suppres-
sion of c-myc.
Downregulation of USP10 Leads to Enhanced Cancer
Cell Proliferation and Tumorigenesis
c-Myc is an oncogenic transcription factor that promotes cell-
cycle progression and tumor growth (Chiswell et al., 1981; Hay-
ward et al., 1981). Therefore, USP10 might antagonize c-Myc
activity to inhibit tumor cell growth though SIRT6 and p53. To
test this hypothesis, we determined whether suppression of
USP10 promotes tumor formation by affecting tumor cell growth.
As expected, USP10 overexpression inhibited the proliferation of
colon cancer cells with either a wild-type p53 or with p53 defi-
ciency. On the other hand, shRNA-mediated USP10 knockdown
caused more vigorous tumor cell growth of both wild-type and
p53-null cells, confirming the tumor-suppressive function of
USP10 (Figures 6A, 6B, S4A, and S4B). SIRT6 knockdown in
p53-null HCT116 colon cancer cells enhanced their proliferation
to a similar level caused by the USP10 knockdown. In contrast,
SIRT6 knockdown in either HCT116 and RKO colon cancer cells
that carry a wild-type p53 gene resulted in a much lower level of
increase in cell proliferation than that of p53-null cell. On the
other hand, SIRT6 knockdown partially abolished the suppres-
sive activity in cancer cell growth by USP10 expression in p53
wild-type, but not p53-null colon cancer cells (Figures 6A, 6B,
S4A, and S4B). Therefore, USP10 suppresses colon cancer
cell growth through both SIRT6 and p53.
We thenused in vitroanchorage-independentcolony formation
assay and analyzed the role of USP10-mediated c-Myc suppres-
sion in tumor formation. USP10 expression in either HCT116 or
RKO colon cancer cells carrying wild-type p53 resulted in a dra-
matic decrease in colony number. Conversely, knockdown of
USP10 expression significantly enhanced the colony formation
(Figures 6C, 6D, S4C, and S4D). However, the suppression of
colon cancer colony formation by gain of USP10 function is
partially abrogated by either loss of p53 or SIRT6 gene knock-
down (Figures 6C and 6D). Therefore, USP10 appears to achieve
its tumor-suppressive function through both SIRT6 and p53. We
further confirmed this conclusion using the xenograft model
(Figures 6E and 6F). When nude mice were implanted with
HCT116 cells, 3 weeks later tumors were formed with average
sizes of 0.5 g. Loss of p53 doubled the average tumor sizes, con-
firming p53 is a tumor suppressor. USP10 stable expression in
p53+/+HCT116 colon cancer cells reduced the tumor sizes to
about 0.3 g in nudemice. Loss ofp53partially abrogated the sup-
pressive activity of USP10 overexpression in tumor formation
because the average tumor weights from the USP10-expression
p53-null HCT116 cells were 0.7 g comparing to 0.3 g by USP10-
expressed p53+/+ HCT116 cells. Similarly, knockdown of SIRT6
partially reversedUSP10 stable expression-mediated tumor sup-
pression in wild-type but not p53-null HCT116 cells. In addition,
knockdown of USP10 expression in wild-type and p53-null
HCT116 cells resulted in the elevated tumor formation by
increasing the average tumor weight to 1.2 and 1.5 g, respec-
tively. Collectively, our results indicate that USP10 suppress
tumorigenesis throughabothp53andSIRT6-dependentmanner.
Decreased expression of USP10 and SIRT6 has been reported
in human primary cancer tissues (Sebastia´n et al., 2012; Yuanports 5, 1639–1649, December 26, 2013 ª2013 The Authors 1645
Figure 6. Downregulation of USP10 Leads to Enhanced Cell Proliferation and Tumorigenesis
(A and B) The cell proliferation of wild-type or p53/ HCT116 cells stably expressing indicated plasmids or combination of plasmids were determined either by
counting cell numbers (A) or by WST-1 assay (B). The error bar represents the SEM of triplicate experiments.
(C and D) Anchorage-independent colony formation of wild-type or p53/ HCT116 cells stably expressing indicated plasmids or combination of plasmids was
determined by soft agar assay. Representative images from three experiments are shown (C). The average number of colonies from three experiments is
indicated (D).
(E and F) (E) Wild-type or p53/HCT116 cells (23 106) stably expressing indicated plasmids or combination of plasmids were injected subcutaneously into nude
mice (n = 3 per group). Three weeks after injection, mice were euthanized, and tumors were isolated and photographed (E) and weighed at the end of the
experiment (F).
(G) Primary human colon cancer tissues (T) and their adjacent normal colon tissues (N) were used for western blotting analysis of the protein expression levels of
USP10, SIRT6, CDC2, and CCNA2. Tubulin was used as loading control.
(H) Total RNA was extracted from corresponding colon cancer tissues (T), and their adjacent normal colon tissues (N) in (G) and the mRNA levels of USP10 or
SIRT6 were analyzed by real-time PCR. The error bars represent the SEM of triplicate experiments.
(I) Our working model of c-Myc and SIRT6 regulation by USP10. Black arrow: known findings; purple arrow: our finding in this study.et al., 2010). Our studies suggest that one of the molecular
mechanisms underlying the decreased protein expression of
SIRT6 is probably impaired USP10 expression. If so, we ex-
pected a positive correlation between the reduced protein ex-
pressions of USP10 and SIRT6. To test this hypothesis, freshly
frozen human colon cancer tissues and adjacent normal tissue
(as controls) were collected. Western blotting showed dramatic
reductions in both USP10 and SIRT6 protein expression levels
in colon cancer tissues compared to controls, indicating that
reduced protein expression of the two tumor-suppressive genes
is involved in human colon cancer development. Importantly and
as expected, the reductions in USP10 and SIRT6 protein expres-
sion in human colon cancers showed a strong positive correla-
tion (Figure 6G). Next, we analyzed the mRNA expression levels1646 Cell Reports 5, 1639–1649, December 26, 2013 ª2013 The Autof both USP10 and SIRT6 in human colon cancer samples using
their adjacent tissues as controls. Results in Figure 6H show that
SIRT6mRNA was reduced in two (#2 and #10) out of ten cancer
patients. However, regardless whether SIRT6 mRNA levels are
reduced in cancer tissues or not, a positive correlation between
the reduced SIRT6 and USP10 protein expression levels was
detected (Figure 6G). These results suggest that SIRT6 protein
expression in human colon cancers was regulated at least
through both mRNA and protein levels. We also analyzed the
mRNA expression levels of USP10 in colon cancer tissue, and
our results show that USP10 mRNA levels are indistinguishable
between cancer and normal tissues, implying that USP10 protein
reduction is through a post-mRNA regulatory mechanism. Inter-
estingly, significant reduction in the protein expression levels ofhors
c-Myc targets, both CDC2 and CCNA2, were detected in human
primary colon cancers (Figure 6G), further supporting our
conclusion that USP10 suppresses tumor through antagonizing
c-Myc transcriptional activation.
Based on these findings, we propose a model of USP10’s
functions as a tumor suppressor (Figure 6I). USP10 deubiquiti-
nates and stabilizes SIRT6, which amplifies the tumor-suppres-
sive activity of SIRT6. USP10 also potentially suppresses tumor
formation by reversing Mdm2-induced p53 nuclear export and
degradation (Yuan et al., 2010). The tumor suppressor USP10
antagonizes the transcriptional activity of the oncogene c-Myc
through both SIRT6 and p53 protein stabilization. In contrast,
reduction in USP10 expression facilitates SIRT6 and p53 protein
degradation through the ubiquitin pathway, resulting in elevated
activation of downstream oncogenes, such as c-myc. Therefore,
the reduced expression of USP10 is positively associated with
human cancer, and this association is presumably involved in
promoting tumor development and progression.
DISCUSSION
Our study demonstrated that USP10 suppresses tumor cell
growth through potentiating both SIRT6- and p53-mediated
suppression of the oncogene c-myc. This conclusion is sup-
ported by the following key discoveries: first, USP10 was identi-
fied as a SIRT6-interacting protein by using a proteomic
approach, and their interaction was confirmed by co-IP and
western blotting. Second, USP10 suppresses SIRT6 ubiquitina-
tion and protects SIRT6 from proteasome-mediated degrada-
tion. Third, USP10 antagonizes c-Myc transcriptional activity
and cell-cycle progression through both SIRT6 and p53. Fourth,
USP10 suppresses human colon cancer cell growth and tumor
formation. In addition, we discovered that the reduced USP10
protein expression levels positively correlated with reduction in
SIRT6 protein expression in human primary colon cancers,
providing a possible molecular explanation for the low SIRT6
level in cancers. These discoveries suggest that crosstalk
between two tumor suppressors is involved in regulating cancer
development and progression.
Several transcription factors, including FOXO3 and AP-1, have
been shown to promote SIRT6 gene expression (Kim et al., 2010;
Min et al., 2012). In addition, a recent study suggested that
microRNA-34a/b targets SIRT6 to regulate fatty acidmetabolism
and insulin signaling (Da´valos et al., 2011). However, whether
and how SIRT6 is regulated at the posttranslational level are
not known. We showed that SIRT6 is extensively ubiquitinated
and quickly degraded in human colon cancer cells. This ubiqui-
tination-mediated degradation is likely through the proteasome,
as treatment of cells with the proteasome inhibitor MG132
blocked SIRT6 degradation. The E3 ubiquitin ligases that
catalyze SIRT6 ubiquitination are not known. Although a
HECT-type E3 ligase, AIP2, was identified as a SIRT6-interacting
protein by our proteomic study, its expression did not enhance
SIRT6 ubiquitination, thereby excluding the possibility that
AIP2 is a ubiquitin ligase of SIRT6. Another possible E3 ubiquitin
ligase is the plant homeodomain (PhD) finger-containing ligase
TRIM28, because it was also identified as a SIRT6-interacting
protein. However, evidence indicates that the PhD finger ofCell ReTRIM28 is a ligase of the small ubiquitin-like modifier (Goodarzi
et al., 2011; Ivanov et al., 2007; Liang et al., 2011). A recent study
has identified CHIP (carboxyl terminus of Hsp70-interacting
protein) as an E3 ubiquitin ligase of Sirt6 (Ronnebaum et al.,
2013); it will be interesting to study the crosstalk among Sirt6,
CHIP, and USP10 during tumorigenesis.
We discovered that USP10 is a deubiquitinase of SIRT6 and
protects SIRT6 from ubiquitination-mediated degradation in
human colon cancer cells. Because the oncogene c-Myc was
recently shown to be a substrate of SIRT6 (Sebastia´n et al.,
2012), it was not surprising that we found that USP10 antago-
nizes c-myc-driven transcriptional activity. USP10 has also
been shown to potentiate the functions of p53, a tumor suppres-
sor that inhibits c-Myc expression (Liu et al., 2011). Consistent
with these discoveries, we demonstrated that p53 is also
involved in USP10-mediated c-Myc suppression, given that
ectopic USP10 expression partially inhibited c-Myc activity in
cancer cells. Therefore, USP10 achieves its tumor-suppressive
activity by stabilizing both SIRT6 and p53 proteins to antagonize
c-Myc transcriptional activity. This discovery implies that in
tumors with loss-of-function mutations in p53 or loss of p53
expression, USP10 suppresses tumor growth through SIRT6-
mediated c-Myc suppression. When either the protein expres-
sion or the function of USP10 is deregulated, both SIRT6 and
p53 proteins lose USP10 protection from ubiquitination-induced
degradation. Consequently, the transcriptional activity of c-Myc
is elevated, leading to tumor development or promotion of tumor
cell growth. Therefore, USP10 achieves its tumor-suppressive
functions by protecting two other tumor suppressors, SIRT6
and p53, from ubiquitination-mediated degradation. Interest-
ingly, both SIRT6 and p53 share the same target—the c-Myc
oncogene. In addition to c-Myc, it has been shown that Sirt6
achieves its function by suppressing HIF-1a (Zhong et al.,
2010). However, our study did not detect any changes in
HIF1-a transcriptional activity by USP10 expression under
normal culture condition. Therefore, it seems that USP10-medi-
ated SIRT6 stabilization is largely involved in regulating c-Myc
transcriptional activity. One speculation is that the USP10 is
specifically directed into the Sirt6/c-Myc but not Sirt6/HIF-1a
complex. Additional efforts are needed to further delineate the
molecular nature of this interesting specificity of USP10 in regu-
lating Sirt6 functions.
Reduced protein expression levels of USP10 or SIRT6 have
been shown in human cancers (Jochemsen and Shiloh, 2010;
Sebastia´n et al., 2012; Yuan et al., 2010). We showed here that
their reduction is positively associated with human colon can-
cers. Based on that finding and our discovery that USP10 is a
deubiquitinase of SIRT6, we speculate that the reduction of
SIRT6 is a consequence of, at least partially, a decrease in
USP10 protein expression. Similarly, a positive correlation was
found between reduced protein expression levels of USP10
and p53 in human clear cell carcinomaswithout p53 (Jochemsen
and Shiloh, 2010; Yuan et al., 2010). However, the correlation
patterns of USP10 with p53 as well as SIRT6 in human cancers
with p53 mutations or deletions are not known. Further studies
are needed to determine whether cooperative regulation of
USP10 and SIRT6 protein expression is associated with p53
expression as well as p53 mutations.ports 5, 1639–1649, December 26, 2013 ª2013 The Authors 1647
EXPERIMENTAL PROCEDURES
Nude Xenograft Mice
All animal-related procedures were performed under the division of laboratory
animal medicine regulations of Northwestern University.
Isolation of SIRT6 Interactors with a Proteomic Approach
HCT116 cells were transfectedwith FLAG-tagged SIRT6 expression plasmids.
The transfected cells were lysed with RIPA buffer and precleaned by incu-
bating them with agarose beads three times. FLAG-tagged SIRT6 proteins
were immunoprecipitated with anti-FLAG (Ab)-conjugated agarose, and the
immune complex was eluted from the agarose with 100 mM FLAG peptide
(Sigma-Aldrich). A small fraction of eluent was subjected to SDS-PAGE anal-
ysis and silver staining using a silver staining kit (Thermo Scientific). The rest
of the eluted proteins were digested with trypsin and characterized by mass
spectrometry.
In Vivo and In Vitro Deubiquitination Assay
For the in vivo ubiquitination assay (Lin et al., 2012), cells were lysed with ubiq-
uitination buffer containing 1% SDS and boiled at 95C for 10 min. The dena-
tured cell lysates were diluted with SDS-negative RIPA buffer to reduce SDS to
0.2% and then subjected to co-IP followed by western blotting with anti-HA or
anti-ubiquitin Abs. The in vitro deubiquitination assay was performed as
described (Shan et al., 2009; Yuan et al., 2010). Briefly, HCT116 cells were
transiently transfected with FLAG-SIRT6 and HA-ubiquitin expression
plasmids. Ubiquitinated SIRT6 proteins were immunoprecipitated with anti-
FLAG -conjugated Sepharose (Sigma-Aldrich) and eluted with the FLAG pep-
tide. The purified ubiquitinated SIRT6 proteins were incubated with GST or
GST-USP10 or GST-USP22 proteins in deubiquitination buffer (50 mM Tris-
HCl [pH 8.0], 50 mM NaCl, 1 mM EDTA, 10 mM DTT, and 5% glycerol) at
37C for 2 hr. SIRT6 ubiquitination was detected by western blotting with
anti-HA Abs.
Chromatin Immunoprecipitation Assay
HCT116 cells were crosslinked with 1% formaldehyde and lysed with SDS
lysis buffer. Cell lysates were sonicated, and 5% of cell lysate was removed
and used to determine the total amount of target DNA in input. Remaining
cell lysates were diluted in chromatin immunoprecipitation (ChIP) dilution
buffer. Immunoprecipitation was performed with each of the indicated anti-
bodies (4 mg) at 4C overnight. Immune complexes were then mixed with
salmon sperm DNA/protein agarose 50% slurry at 4C for 1 hr. After immuno-
precipitates were washed sequentially with low-salt buffer, high-salt buffer,
LiCl wash buffer, and Tris EDTA DNA-protein complexes were eluted with
elution buffer, and crosslinking was reversed. Genomic DNA was extracted
using phenol/chloroform, and ethanol-precipitated DNA was resuspended in
Tris EDTA. PCR was performed with specific primers (QIAGEN) according to
the manufacturer’s protocol (Millipore).
Cell-Cycle Analysis
HCT116 cells were seeded in a 6-well dish at 1 3 106 cells per well 1–2 days
prior to analysis. The cells were collected and fixed in precooled ethanol and
incubated at 20C overnight. Cells were treated with 100 mg/ml RNase in
PBS, washed, and stained with 5 mg/ml of propidium iodide. After washing
with ice-cold PBS twice, cells were analyzed by flow cytometry and Flowjo
software.
RNA Extraction and Real-Time PCR Analysis of Gene Expression
Total RNA was extracted using Trizol reagent (Invitrogen) as described (Lee
et al., 2008). Quantitative real-timeRT-PCRwas performed using SYBR-Green
qPCR master mix (Clontech Laboratories). The b-actin gene was used as a
reference for sample normalization. Primers for mouse or human genes,
including b-actin, usp22, usp10, and SIRT6, were purchased from RealTime
Primers. A standard amplification protocol was used according to the
manufacturer’s instructions. c-Myc target gene primers were cdc2 forward:
50-CAGTCTTCAGGATGTGCTTATGC-30, cdc2 reverse: 50-GAGGTTTTAAG
TCTCTGTGAAGAACTC-30; PCNA forward: 50-AGGGCTCCATCCTCAAGA
AGG-30; PCNA reverse: 50-TGGTGCTTCAAATACTAGCGC-30; cyclinA2 for-1648 Cell Reports 5, 1639–1649, December 26, 2013 ª2013 The Autward: 50-GAAGACGAGACGGGTTGCA-30 CyclinA2 reverse: 50-AGGAGGA
ACGGTGACATGCT-30; Cdc25c forward: 50-GAACAGGCCAAGACTGAAGC-
30 cdc25c reverse: 50-GCCCCTGGTTAGAATCTTCC-30.
Cell Proliferation Assay
In vitro cell proliferation was measured by using the colorimetric WST-1 assay
(cell proliferation reagent WST-1, Roche Diagnostics). Briefly, 4,000 cells were
seeded in a 96-well plate with DMEM containing 10% fetal bovine serum.
Every 24 hr, 10 ml of WST-1 reagent was added to each well followed by incu-
bation for 2 hr. The absorbance at 450 nm was measured using a microplate
reader.
Soft Agar Colony Formation Assay
HCT116 or RKO cells were suspended at low density (0.753 104 cells) in 3 ml
of culture medium containing 0.3% agar (USB Corporation) and seeded onto a
base layer of 3ml of 0.6%agar in 60mm tissue culture dishes. After 3–4weeks,
colonies were stained, photographed, and scored.
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